
PACS Stock Forecast & Price Target
PACS Analyst Ratings
Bulls say
PACS Group is well-positioned to thrive in the post-acute healthcare market with its strong focus on skilled nursing care and diversified portfolio of services for seniors. The company's impressive financial performance, highlighted by a 2027E adjusted EBITDA of $649.0M and a leading scale in the market, makes it a compelling investment opportunity with strong secular industry tailwinds. Its decentralized operating model, robust technology assets, and strong financial flexibility provide a competitive edge in adapting to local dynamics and driving attractive benefits in payor contracting and referral source relationships. However, potential regulatory risks, government reimbursement concerns, and integration challenges for acquisitions could pose risks to its growth trajectory.
Bears say
PACS Group is well-positioned in the post-acute healthcare market with a strong presence in key markets and attractive clinical capabilities; however, its current leverage position of 0.3X adj. EBITDA may limit its ability to complete significant M&A deals in the near future. Furthermore, while the company's M&A pipeline appears strong, the potential for overpaying for deals in competitive markets may pose a risk to its overall financial health.
This aggregate rating is based on analysts' research of PACS Group, Inc. and is not a guaranteed prediction by Public.com or investment advice.
PACS Analyst Forecast & Price Prediction
Start investing in PACS
Order type
Buy in
Order amount
Est. shares
0 shares